MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, IXHL had $2,237K increase in cash & cash equivalents over the period. -$2,461K in free cash flow.

Cash Flow Overview

Change in Cash
$2,237K
Free Cash flow
-$2,461K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from share issuance
    • Stock-based compensation expense
    • Trade and other payables
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Share repurchase
    • Share issuance costs
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Effect of exchange rate changes on cash
--388 269 -
Net loss
-3,883 -6,521 -6,407 -46,885
Depreciation and amortization
65 59 66 246
Unrealized loss on foreign currency remeasurement
25 -24 -13 -294
Stock-based compensation expense
1,469 2,279 2,626 2,609
Change in fair value of warrant liabilities
-380 --21,925
Prepaid expenses and other current assets
-26 -51 -299 189
R&d tax incentive
186 558 364 -5,579
Trade and other payables
458 44 -5,396 1,385
Non-cash expense of eloc commitment
0 --1,048
Change in fair value of convertible rights
0 ---299
Non-cash interest expense
0 --302
Loss on extinguishment
0 ---1,472
Securities pledged
0 ---
Net cash used in operating activities
-2,456 -4,622 -9,163 -12,513
Purchase of property, plant and equipment
5 4 2 8
Investment of joint venture
13 0 40 -
Net cash used in investing activities
-18 -4 -42 -8
Proceeds from share issuance
6,955 2,197 69,465 48,343
Share issuance costs
823 91 2,288 747
Warrant issuance costs
284 --125
Share repurchase
1,138 1,179 --
Proceeds received from facility agreement
0 --4,282
Repayment of facility agreement
0 --4,459
Proceeds from issuance of convertible debt
0 --2,779
Cancellation of warrants
---24,769
Repayment of convertible debt
0 --3,795
Debt issuance costs
0 --113
Net cash provided by financing activities
4,710 927 67,177 21,396
Net increase in cash and cash equivalents
2,237 -3,700 57,972 8,875
Cash and cash equivalents at beginning of period
69,193 73,280 15,039 -
Cash and cash equivalents at end of period
74,450 69,193 73,280 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from shareissuance$6,955K Net cash provided byfinancing activities$4,710K Canceled cashflow$2,245K Net increase in cashand cash...$2,237K Canceled cashflow$2,474K Share repurchase$1,138K Share issuance costs$823K Warrant issuance costs$284K Stock-based compensationexpense$1,469K Trade and otherpayables$458K Depreciation andamortization$65K Prepaid expenses andother current assets-$26K Net cash used inoperating activities-$2,456K Net cash used ininvesting activities-$18K Canceled cashflow$2,018K Net loss-$3,883K Investment of joint venture$13K Purchase of property,plant and equipment$5K Change in fair value ofwarrant liabilities-$380K R&d tax incentive$186K Unrealized loss on foreigncurrency remeasurement$25K

Incannex Healthcare Inc. (IXHL)

Incannex Healthcare Inc. (IXHL)